Published in Clin Pharmacol Ther on April 01, 2005
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost (2014) 0.95
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res (2007) 0.95
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One (2011) 0.88
Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol (2013) 0.88
HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity. PLoS One (2017) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med (2003) 3.32
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology (2014) 2.12
Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol (2006) 1.95
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrol Dial Transplant (2005) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med (2016) 1.60
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res (2011) 1.57
The prognosis for individuals on disability retirement. An 18-year mortality follow-up study of 6887 men and women sampled from the general population. BMC Public Health (2006) 1.54
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost (2010) 1.47
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
[Diagnosis of acute pulmonary embolism. Simplified strategy based on clinical probability, D-dimer and computer tomography]. Lakartidningen (2006) 1.40
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost (2012) 1.37
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother (2006) 1.36
Cervical artery dissection: pathology, epidemiology and management. Thromb Res (2009) 1.33
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res (2002) 1.30
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed (2012) 1.27
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn (2004) 1.24
Sick-leave track record and other potential predictors of a disability pension. A population based study of 8,218 men and women followed for 16 years. BMC Public Health (2009) 1.23
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol (2004) 1.22
Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn (2002) 1.19
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J (2005) 1.19
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol (2003) 1.18
Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn (2002) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J (2012) 1.16
Semiparametric distributions with estimated shape parameters. Pharm Res (2009) 1.15
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother (2012) 1.13
Performance in population models for count data, part I: maximum likelihood approximations. J Pharmacokinet Pharmacodyn (2009) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.11
Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost (2006) 1.09
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res (2006) 1.06
A fast method for testing covariates in population PK/PD Models. AAPS J (2011) 1.05
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol (2003) 1.04
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res (2011) 1.03
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol (2003) 1.02
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn (2008) 1.01
Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn (2009) 1.01
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Effects of self-rated health on sick leave, disability pension, hospital admissions and mortality. A population-based longitudinal study of nearly 15,000 observations among Swedish women and men. BMC Public Health (2012) 1.01
Mechanistic models for myelosuppression. Invest New Drugs (2003) 1.00
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models. AAPS J (2012) 0.99
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 0.97
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol (2007) 0.97
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol (2004) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol (2007) 0.96
Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci (2008) 0.95
Application of population pharmacokinetics to cladribine. BMC Pharmacol (2005) 0.95
Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public Health (2008) 0.95
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn (2010) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95